Kwonjune Justin Seung, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis, Multidrug-Resistant | 45 | 2024 | 910 | 7.270 |
Why?
|
| Antitubercular Agents | 43 | 2024 | 1319 | 5.650 |
Why?
|
| Nitroimidazoles | 6 | 2022 | 106 | 1.970 |
Why?
|
| Tuberculosis, Pulmonary | 12 | 2018 | 810 | 1.750 |
Why?
|
| Oxazoles | 6 | 2022 | 189 | 1.120 |
Why?
|
| Lesotho | 11 | 2024 | 70 | 0.930 |
Why?
|
| Rifampin | 10 | 2023 | 315 | 0.860 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 6 | 2023 | 92 | 0.630 |
Why?
|
| Clofazimine | 5 | 2023 | 33 | 0.630 |
Why?
|
| Tuberculosis | 5 | 2020 | 1904 | 0.600 |
Why?
|
| Financial Management | 1 | 2018 | 160 | 0.560 |
Why?
|
| Financing, Organized | 1 | 2018 | 202 | 0.560 |
Why?
|
| Mycobacterium tuberculosis | 7 | 2020 | 1825 | 0.510 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 1071 | 0.510 |
Why?
|
| Isoniazid | 4 | 2015 | 273 | 0.500 |
Why?
|
| Fluoroquinolones | 6 | 2023 | 308 | 0.480 |
Why?
|
| HIV Infections | 10 | 2024 | 16678 | 0.470 |
Why?
|
| Capacity Building | 1 | 2016 | 248 | 0.470 |
Why?
|
| Mycobacterium | 1 | 2013 | 249 | 0.410 |
Why?
|
| Sputum | 6 | 2024 | 474 | 0.390 |
Why?
|
| International Cooperation | 1 | 2018 | 1421 | 0.390 |
Why?
|
| Comprehensive Health Care | 1 | 2012 | 127 | 0.390 |
Why?
|
| Bacterial Shedding | 1 | 2010 | 10 | 0.380 |
Why?
|
| Antibiotics, Antitubercular | 3 | 2018 | 104 | 0.360 |
Why?
|
| Hepatitis C | 1 | 2020 | 1582 | 0.350 |
Why?
|
| Drug Therapy, Combination | 9 | 2023 | 6483 | 0.340 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 654 | 0.330 |
Why?
|
| Thyrotropin | 1 | 2012 | 850 | 0.320 |
Why?
|
| Malaria | 1 | 2018 | 1232 | 0.310 |
Why?
|
| Treatment Outcome | 22 | 2024 | 62966 | 0.290 |
Why?
|
| Hypothyroidism | 1 | 2012 | 659 | 0.290 |
Why?
|
| Salvage Therapy | 1 | 2013 | 1269 | 0.290 |
Why?
|
| Pyrazinamide | 3 | 2018 | 54 | 0.280 |
Why?
|
| Patient Simulation | 1 | 2008 | 308 | 0.280 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 722 | 0.280 |
Why?
|
| Democratic People's Republic of Korea | 2 | 2016 | 12 | 0.260 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2013 | 1032 | 0.250 |
Why?
|
| Respiratory Tract Infections | 1 | 2012 | 959 | 0.240 |
Why?
|
| Ethambutol | 2 | 2018 | 60 | 0.220 |
Why?
|
| Kanamycin | 3 | 2018 | 64 | 0.220 |
Why?
|
| Directly Observed Therapy | 4 | 2008 | 137 | 0.220 |
Why?
|
| Health Resources | 1 | 2008 | 911 | 0.210 |
Why?
|
| Humans | 61 | 2024 | 742088 | 0.200 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 4929 | 0.190 |
Why?
|
| Anti-HIV Agents | 2 | 2013 | 4250 | 0.180 |
Why?
|
| Capreomycin | 2 | 2018 | 14 | 0.160 |
Why?
|
| Drug Repositioning | 1 | 2020 | 229 | 0.160 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2014 | 1871 | 0.160 |
Why?
|
| Prevalence | 6 | 2020 | 15194 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1661 | 0.150 |
Why?
|
| Curriculum | 1 | 2008 | 3589 | 0.130 |
Why?
|
| Health Personnel | 1 | 2008 | 3210 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 2276 | 0.120 |
Why?
|
| World Health Organization | 4 | 2023 | 1317 | 0.120 |
Why?
|
| Korea | 2 | 2004 | 99 | 0.120 |
Why?
|
| Administration, Oral | 2 | 2019 | 3913 | 0.120 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2013 | 30 | 0.120 |
Why?
|
| Clarithromycin | 1 | 2013 | 86 | 0.110 |
Why?
|
| Clinical Protocols | 3 | 2024 | 1459 | 0.110 |
Why?
|
| Community Health Services | 2 | 2015 | 650 | 0.110 |
Why?
|
| Primary Health Care | 3 | 2014 | 4551 | 0.110 |
Why?
|
| HIV Seroprevalence | 1 | 2012 | 86 | 0.110 |
Why?
|
| Adult | 22 | 2021 | 213712 | 0.100 |
Why?
|
| Maternal Welfare | 1 | 2012 | 115 | 0.100 |
Why?
|
| Streptomycin | 2 | 2018 | 69 | 0.100 |
Why?
|
| Electrolytes | 2 | 2022 | 282 | 0.100 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2004 | 563 | 0.100 |
Why?
|
| Retrospective Studies | 12 | 2013 | 77098 | 0.100 |
Why?
|
| Female | 24 | 2024 | 379592 | 0.090 |
Why?
|
| National Health Programs | 2 | 2004 | 445 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2023 | 9941 | 0.090 |
Why?
|
| Africa, Southern | 1 | 2009 | 57 | 0.090 |
Why?
|
| Prospective Studies | 6 | 2024 | 53187 | 0.090 |
Why?
|
| Public Health | 1 | 2023 | 2594 | 0.090 |
Why?
|
| Drug Design | 1 | 2015 | 1078 | 0.090 |
Why?
|
| Pneumonectomy | 1 | 2016 | 1093 | 0.080 |
Why?
|
| Male | 21 | 2021 | 349538 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2015 | 2026 | 0.080 |
Why?
|
| Anti-Retroviral Agents | 2 | 2008 | 1712 | 0.080 |
Why?
|
| Drug Resistance, Viral | 1 | 2013 | 820 | 0.080 |
Why?
|
| Cohort Studies | 7 | 2022 | 40450 | 0.080 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 3843 | 0.070 |
Why?
|
| Maternal Health Services | 1 | 2012 | 452 | 0.070 |
Why?
|
| Adolescent | 9 | 2021 | 85649 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2012 | 956 | 0.070 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 941 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 7276 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 1411 | 0.070 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 1265 | 0.060 |
Why?
|
| Siberia | 1 | 2004 | 32 | 0.060 |
Why?
|
| Middle Aged | 10 | 2021 | 213127 | 0.060 |
Why?
|
| Treatment Failure | 3 | 2018 | 2615 | 0.060 |
Why?
|
| Prothionamide | 1 | 2004 | 3 | 0.060 |
Why?
|
| Aminosalicylic Acid | 1 | 2004 | 21 | 0.060 |
Why?
|
| Ofloxacin | 1 | 2004 | 65 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2014 | 1852 | 0.060 |
Why?
|
| Young Adult | 6 | 2021 | 56350 | 0.060 |
Why?
|
| Cycloserine | 1 | 2004 | 113 | 0.060 |
Why?
|
| Self Administration | 1 | 2004 | 386 | 0.050 |
Why?
|
| Child | 5 | 2021 | 77478 | 0.050 |
Why?
|
| Algorithms | 1 | 2023 | 13853 | 0.050 |
Why?
|
| Drug Resistance, Multiple | 1 | 2003 | 252 | 0.050 |
Why?
|
| Public Sector | 1 | 2003 | 264 | 0.050 |
Why?
|
| Administrative Personnel | 1 | 2023 | 187 | 0.050 |
Why?
|
| Pregnancy | 4 | 2024 | 29087 | 0.050 |
Why?
|
| Developing Countries | 1 | 2014 | 2789 | 0.050 |
Why?
|
| Acute Disease | 1 | 2012 | 7141 | 0.050 |
Why?
|
| Delivery of Health Care | 3 | 2014 | 5304 | 0.050 |
Why?
|
| Patents as Topic | 1 | 2021 | 103 | 0.050 |
Why?
|
| Private Sector | 1 | 2003 | 390 | 0.050 |
Why?
|
| Live Birth | 1 | 2024 | 512 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 2231 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 839 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2012 | 40955 | 0.040 |
Why?
|
| Off-Label Use | 1 | 2020 | 169 | 0.040 |
Why?
|
| Amikacin | 1 | 2018 | 48 | 0.040 |
Why?
|
| Peru | 3 | 2008 | 881 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 2275 | 0.040 |
Why?
|
| Comorbidity | 1 | 2012 | 10372 | 0.040 |
Why?
|
| Carbapenems | 1 | 2018 | 117 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 57683 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2012 | 9144 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 4379 | 0.040 |
Why?
|
| Health Literacy | 1 | 2021 | 414 | 0.030 |
Why?
|
| HIV | 1 | 2024 | 1600 | 0.030 |
Why?
|
| Review Literature as Topic | 1 | 2018 | 333 | 0.030 |
Why?
|
| Bone Morphogenetic Proteins | 2 | 1997 | 838 | 0.030 |
Why?
|
| Forecasting | 1 | 2003 | 2948 | 0.030 |
Why?
|
| Retreatment | 2 | 2006 | 604 | 0.030 |
Why?
|
| Recurrence | 2 | 2018 | 8333 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 627 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2023 | 1768 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2021 | 2303 | 0.030 |
Why?
|
| Nurse Midwives | 1 | 2012 | 23 | 0.030 |
Why?
|
| Health Policy | 1 | 2003 | 2657 | 0.020 |
Why?
|
| Midwifery | 1 | 2012 | 131 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 24913 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2014 | 9846 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 8621 | 0.020 |
Why?
|
| Research Design | 1 | 2006 | 5979 | 0.020 |
Why?
|
| Aged | 3 | 2021 | 162944 | 0.020 |
Why?
|
| Maternal Mortality | 1 | 2012 | 310 | 0.020 |
Why?
|
| Muscles | 1 | 1994 | 1617 | 0.020 |
Why?
|
| Point Mutation | 1 | 1994 | 1624 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 1997 | 1786 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2008 | 211 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 1994 | 1416 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2970 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2024 | 12695 | 0.020 |
Why?
|
| Program Development | 1 | 2012 | 1314 | 0.020 |
Why?
|
| Obstetrics | 1 | 2012 | 657 | 0.020 |
Why?
|
| Delivery, Obstetric | 1 | 2012 | 904 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2012 | 1088 | 0.020 |
Why?
|
| Mice, Inbred C3H | 2 | 1997 | 964 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2005 | 768 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 6365 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 10943 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1994 | 2575 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2024 | 25575 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2008 | 1849 | 0.010 |
Why?
|
| Disease Management | 1 | 2014 | 2450 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8328 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 39004 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 2795 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2003 | 375 | 0.010 |
Why?
|
| Risk Factors | 3 | 2014 | 72145 | 0.010 |
Why?
|
| Proteins | 1 | 1994 | 6096 | 0.010 |
Why?
|
| Social Support | 1 | 2008 | 2117 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2008 | 2706 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 2 | 1997 | 6171 | 0.010 |
Why?
|
| Base Sequence | 2 | 1997 | 12797 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1994 | 427 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1997 | 13814 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1997 | 2049 | 0.010 |
Why?
|
| Codon | 1 | 1994 | 611 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1997 | 1263 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1997 | 18112 | 0.010 |
Why?
|
| Growth Substances | 1 | 1994 | 783 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 12958 | 0.010 |
Why?
|
| Ureter | 1 | 1994 | 374 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1994 | 1866 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 40054 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 2892 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 1994 | 1171 | 0.000 |
Why?
|
| Incidence | 1 | 2006 | 20928 | 0.000 |
Why?
|
| Reference Values | 1 | 1994 | 4982 | 0.000 |
Why?
|
| Protein Biosynthesis | 1 | 1994 | 2126 | 0.000 |
Why?
|
| Gestational Age | 1 | 1994 | 3490 | 0.000 |
Why?
|
| Intestines | 1 | 1994 | 1923 | 0.000 |
Why?
|
| Gene Expression | 1 | 1994 | 7790 | 0.000 |
Why?
|
| Liver | 1 | 1994 | 7470 | 0.000 |
Why?
|
| Mice | 2 | 1997 | 81045 | 0.000 |
Why?
|
| Lung | 1 | 1994 | 9826 | 0.000 |
Why?
|
| Animals | 2 | 1997 | 168561 | 0.000 |
Why?
|